We have a wealth of experience in editing the genome using one of the many currently available forms of Cas9-derived nucleases, including some of the newer versions with improved fidelity and increased target assignment versatility.
StemCore has an extensive experience in both NHEJ and HDR-driven mutagenesis in human stem cells, including traceless correction of genetic mutations, and is able to assist you with the widest range of the human genome modification needs.
Correction of ATM mutations in iPS cells from two ataxia-telangiectasia patients restores DNA damage and oxidative stress responses 2020 Human Molecular Genetics DA Ovchinnikov, SL Withey, HC Leeson, UW Lei, A Sundarrajan et al.
The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived Neurons 2018. Stem Cell Reports Ovchinnikov DA, Korn, O, Virshup, I., Wells, CA, Wolvetang EJ
Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns. 2018 APL Bioengineering S Alateeq, D Ovchinnikov, T Tracey, D Whitworth, A Al-Rubaish, A Al-Ali, Wolvetang, E.
